Table of Contents
I. $1000 Prize to anyone who can break this Code http://hegp.genenetwork.org/challenge
II. Adolescent Brain Cognitive Development SM (ABCD) Study COVID-19 supplemental data release is now available on the NIMH Data Archive(NDA) NDA website
III. Call for Abstracts for NIDA Genetics and Epigenetics Consortium Meeting Due Feb 1, 2021
I. $1000 Prize to anyone who can break this Code http://hegp.genenetwork.org/challenge
Richard Mott and Pjotr Prins developed a homomorphic encryption method for genotypes and phenotypes (HEGP) as described in this open access paper supported by NIDA P30DA044223, NIGMS R01 GM-123489, and Biotechnology and Biological Sciences Research Council grants BB/S017372/1, BB/R01356X/1, HBB/P024726/1, and BB/M011585/1. HEGP mixes up genotypes and phenotypes to make them indistinguishable from random numbers, but such that the randomization has no effect on the outcome of testing genetic association or of estimating key parameters such as heritability or the effects of individual genetic variants. It makes it possible to share encrypted datasets and perform large-scale federated mega-analyses as if the unencrypted data had been shared. Richard Mott and Pjotr Prins are offering a $1000 Prize to anyone who can break the code http://hegp.genenetwork.org/challenge. Please forward to anyone with code breaking expertise.
II. Adolescent Brain Cognitive Development SM (ABCD) Study COVID-19 supplemental data release is now available on the NIMH Data Archive(NDA) NDA website
The ABCD COVID-19 data release consists of survey responses from ABCD families about the impact of the pandemic on their lives. Surveys were sent electronically to all ABCD participants and their parent/guardian in May, June, August and December of 2020. Youth and parents/guardians were asked separately about school attendance and activities, sleep, daily routines, physical activity, mental health, screen time, racism/discrimination in relation to COIVD-19, COVID attitudes and practices, and coping behaviors. Importantly, researchers will be able to link data from these surveys to data from the main ABCD study visits, including those that occurred prior to the pandemic. Future releases will include data from subsequent surveys. Visit the NDA website for more information.
III. Call for Abstracts for NIDA Genetics and Epigenetics Consortium Meeting Due Feb 1, 2021
The Genetics and Epigenetics Cross Cutting Research Team of the National Institute on Drug Abuse invites you to submit an abstract for the March 8-10, 2021 Virtual NIDA Genetics and Epigenetics Consortium Meeting. Oral presentations will be conducted through Webex. Submissions selected for poster presentations will have the opportunity to present their work through a SLACK Channel. Presenters using a SLACK channel must post hyperlinks to their presentations. Presentations uploaded as a file to SLACK will be removed. We encourage hyperlinks to short (e.g. 5 to 10 slides) slide decks (e.g. via Box, Google Drive or other data-sharing service) and presentations via Zoom or other similar platform. Detailed instructions will be shared in mid-February and practice sessions will be held prior to the meeting.
Please submit your abstract in the following format to NIDAGenetics@leedmci.com. By February 1, 2021:
Submitter Name:
Submitted email:
PI Name (if different):
PI email (if different):
Clever title for your abstract
First Name Last Name1, First Name Last Name1,2, First Name Last Name3, and First Name Last Name1,4
1Department, University; 2Department, University; 3Department, University; 4Department, University
The Abstract should discuss the background, rationale/significance, hypothesis, results and discussion. The font size should be Arial 11 pt. The body of the abstract should be 250 words, maximum and fully justified. Please submit the abstract as a word document. Abstracts are due by Midnight PST on February 1, 2021. Abstracts not conforming to this format or sent to another email will not be accepted for review and may be returned to the sender. Abstracts sent to another email will not be returned.
See examples at: (2020 NIDA Genetics Consortium Meeting Abstracts).
The goals of the meeting are to:
- Showcase the exciting research on the genetics and epigenetics of substance use disorders
- Encourage collaboration among investigators with different expertise in genetics and epigenetics
- Foster collaboration between investigators working on the genetics and epigenetics of substance abuse disorders and HIV/AIDS investigators
- Identify new research opportunities in the genetics and epigenetics of substance use disorders
- Provide attendees with an opportunity to meet with NIDA program directors to discuss their ideas for grant applications and funding opportunities
The NIDA Genetics and Epigenetics Cross-Cutting Research Team will select up to 30 abstracts for short talks. We may invite some investigators to serve as panel discussants. Abstracts not selected for talks may be assigned poster presentations. Abstracts should focus on the genetics and epigenetics of substance abuse in humans or in model systems. We encourage submissions across all career stages (e.g. graduate students, postdoctoral scientists, junior and senior faculty). Abstracts are due by Midnight PST on Monday, February 1, 2021. Decisions on acceptance of poster presentations and short talks will be made on a rolling basis.
----------------------
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L
No comments:
Post a Comment